Saturday, July 11, 2026

FDA · United States

amoxicillin — FDA regulatory status

amoxicillin (ALPHAMOX 250) regulatory status in the United States is tracked from public FDA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: FDA approved.

Status snapshot

Status
FDA approved
Brand
ALPHAMOX 250
Originator
Alphapharm Pty Ltd
Mechanism
Bacterial penicillin-binding protein inhibitor
Target
Bacterial penicillin-binding protein
Structured fields
8

Sponsor / originator context: Alphapharm Pty Ltd. Pipeline programs and exclusivity signals below are joined from ClinicalTrials.gov-linked projects and USPTO/EPO patent rows associated with this INN.

Pharmacology context used for competitive intelligence: Bacterial penicillin-binding protein inhibitor. Target: Bacterial penicillin-binding protein. This page is a status aggregation for professional reference — not prescribing advice.

Regional decision snapshot — FDA: approved.

Linked evidence on this spoke: 53 published clinical programs and 12 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.

Regulatory timeline

Regulator Region Status Date Source
FDA United States approved Evidence

Linked clinical programs

Program Phase Sponsor NCT
600 mg Ibuprofen Phase 3 United Therapeutics Europe NCT07006675
9999 Phase 3 United Therapeutics Europe NCT00396526
APHP200011 Phase 3 PARItec 2024-513327-16-00
APHP220763 Phase 3 PARItec 2024-514952-34-00
APHP220814 Phase 3 PARItec 2023-504208-27-00
APHP230841 Phase 3 PARItec 2025-520842-31-00
APHP241013 Phase 3 PARItec 2025-521571-30-00
Amoxycillin Phase 3 United Therapeutics Europe NCT00407394
BEP(500) Phase 3 United Therapeutics Europe NCT01726374
Co-Trimoxazole 960Mg Dispersible Tablet Phase 3 United Therapeutics Europe NCT04395365
Generic Budesonide/Formoterol Fumarate Dihydrate Phase 3 Teva Pharma NCT02495168
Generic Estradiol Vaginal Cream USP, 0.01% Phase 3 Teva Pharma NCT03294538

Related patents

Number Title Jurisdiction
2026015039 THÉRAPIE GÉNIQUE POUR LE TRAITEMENT DE L'ENCÉPHALOPATHIE ÉPILEPTIQUE ASSOCIÉE À LA SYNGAP1 WO
2025211975 AGONISTES DU RÉCEPTEUR DE L'OREXINE WO
12076377 Variant sulfatase enzymes with enhanced properties US
11931463 All-in-one fixed-dose combination for treating Helicobacter pylori infection US
11878011 Method for eradicating Helicobacter pylori infection in patients regardless of body mass index US
11154614 Method for producing virus like particles US
11135172 Rifabutin-based compositions and methods for treating Helicobacter pylori infection US
11028153 Targeting immunological functions to the site of bacterial infections using cell wall targeting domains of bacteriolysins US
10487140 Targeting immunological functions to the site of bacterial infections using cell wall targeting domains of bacteriolysins US
10238606 Pharmaceutical compositions for the treatment of Helicobacter pylori US
10233450 Methods and compositions for the specific inhibition of gene expression by double-stranded RNA US
10106792 Methods and compositions for the specific inhibition of gene expression by double-stranded RNA US

Related hubs

FAQ

What is the FDA approval status of amoxicillin?

amoxicillin currently shows FDA approved in our United States regulatory index. Confirm on the official FDA label or EPAR before clinical or commercial use.

Where does NovaPharmaNews get amoxicillin regulatory data?

Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.

How many clinical programs are linked to amoxicillin?

This spoke lists 53 published programs associated with amoxicillin in our pipeline index.